

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 07-1293)**

<b>U.S. Patent No.:</b>	<b>6,395,767</b>	)
		)
<b>Granted:</b>	<b>May 28, 2002</b>	)
		)
<b>Inventors:</b>	<b>Robl <i>et al.</i></b>	)
		)
<b>Serial No.:</b>	<b>09/788,173</b>	)
		)
<b>Filed:</b>	<b>February 6, 2001</b>	)
		)
<b>For:</b>	<b>Cyclopropyl-fused</b>	)
	<b>Pyrrolidine-based Inhibitors of</b>	)
	<b>Dipeptidyl Peptidase IV and</b>	)
	<b>Method</b>	)

**SUPPLEMENT TO APPLICATION FOR PATENT TERM EXTENSION  
FILED SEPTEMBER 22, 2009**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22303-1450

Dear Sir:

Responsive to an informal telephone inquiry from Mary C. Till, Legal Advisor, Office of Patent Legal Administration, Applicant submits herewith this supplement to its Application for Patent Term Extension, filed September 22, 2009. Pursuant to the provisions of 37 C.F.R. §1.765, Applicant wishes to clarify the information submitted in its application pursuant to 37 C.F.R. §1.740(a)(1) regarding the drug product. Specifically, the form of ONGLYZA<sup>®</sup> (generic name: saxagliptin), an anti-diabetic drug having the chemical name (1S,3S,5S)-2-[(2S)-amino(3-hydroxytricyclo[3.3.1.1<sup>3,7</sup>]dec-1-

yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, as provided in the drug product is the hydrated hydrochloride salt thereof, as set forth in Exhibit C of Applicant's application as filed.

If the Examiner or Patent Office official reviewing this application believes it to be helpful, she is invited to contact the undersigned attorney by telephone at (312) 913-0001.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Date: February 2, 2010

By: /Kevin E. Noonan/  
Kevin E. Noonan  
Reg. No. 35,303